Seattle Genetics stops Phase III trial of leukaemia drug due to high death rate
Biotechnology firm Seattle Genetics has stopped the Phase III CASCADE clinical trial of vadastuximab talirine (SGN-CD33A) in older patients with frontline acute myeloid leukaemia (AML).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Acute Leukemia | Acute Myeloid Leukemia | Biotechnology | Clinical Trials | Genetics | Leukemia | Pharmaceuticals